These data provided the rationale for the phase III EMERALD study comparing the efficacy and safety of elacestrant versus standard-of-care endocrine treatment (fulvestrant or AI) in patients with ER+, HER2− advanced breast cancer (66). The gene discussed is ERBB2; the disease is breast cancer.